Test antibody treatment for chronic hepatitis B
Treatments studied
Part of Digestive system, Infections clinical trials.
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 70 and able to give informed consent
- Have confirmed hepatitis B infection for at least 6 months (positive HBsAg for 6+ months)
- Be on hepatitis B antiviral therapy for at least 6 months, without changing to a different NRTI in the last 3 months
- Recent blood and safety checks must fit the trial lab limits (for example: very low HBV DNA, certain liver and blood counts, and acceptable kidney/INR values)
- Have milder liver scarring only (FibroScan showing fibrosis grade 1–2, not grade 3–4, within the last 12 months or at the pre-infusion visit)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests an experimental vaccine therapy to help control or possibly cure chronic hepatitis B. It is designed to see whether the treatment is safe and how well it affects the hepatitis B virus in adults.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.